Techna’s Post

Upcoming Webinar: QIPCM - UHN's Imaging Core Lab Enhancing cancer research with quantitative imaging: A deep dive into QIPCM at UHN Join us for an engaging webinar on June 27th at 11:30 am that showcases the Quantitative Imaging for Personalized Cancer Medicine (QIPCM) program which provides end-to-end testing and analysis support for clinical trials to improve consistency and reliability in clinical trial imaging data. Gain insights from our expert speakers as they delve into the capabilities of QIPCM and share detailed case studies. Learn more about QIPCM before the webinar at QIPCM.com Don’t miss this opportunity to learn more about QIPCM and discover how QIPCM can streamline your approach to clinical research. Register today to secure your virtual seat! Register @ t.ly/aUM5k Agenda: 1. QIPCM Overview & Highlight Discover the core features and significant benefits of QIPCM’s innovative platform. 2. Unveiling QIPCM Development Projects Presentation of the QIPCM platform and the new features our team is working on. 3. Case Studies Showcase Detailed discussions about pivotal trials, the challenges faced, and the innovative solutions within our fields of medical imaging, radiotherapy, and theranostics. 4. Interactive Q&A Session Participate in a live Q&A with our experts to gain a deeper understanding of QIPCM's functionalities and its applications in your field.

Transforming Radiation Oncology: How AI and Automation are Enhancing Cancer Treatment 🌟 Embracing the Future of Cancer Treatment 🌟 Automation and artificial intelligence are revolutionizing the field of radiation oncology, offering unprecedented enhancements in precision and efficiency. From breast radiotherapy to predicting lymph node metastasis, the integration of these cutting-edge technologies holds the promise of transforming patient outcomes and elevating the standard of care. ✨ Interpreting AI with Transparency ✨ The journey towards fully leveraging AI in clinical settings emphasizes the development of interpretable models. Transparent and reliable AI ensures trust and efficacy in decision-making, empowering healthcare professionals to deliver innovative cancer treatments with confidence. 🚀 Together, advancing the frontiers of radiation oncology, we can make these life-changing technologies a reality for patients everywhere. 🚀 The ideas presented here are derived from the following article: https://lnkd.in/g46EyhDC [#AICancerCare, #FutureOfOncology] Inspired by these concepts, we're refining Dr. Persona AI, our AI-powered Learning Management System, to deliver a more tailored and impactful learning journey in Radiotherapy.

🌟ART-Plan Precision Radiotherapy now integrated into MedAustron's clinical workflow! 🌟 📈At TheraPanacea, we're ecstatic to announce the adoption from MedAustron Particle Therapy Center of our AI-powered ART-Plan Precision Radiotherapy Solution to the forefront of cancer treatment. This is a testament to our shared vision of harnessing the power of artificial intelligence to transform patient care. 🏥The MedAustron Particle Therapy Center in Austria excels in cancer treatment using advanced proton and carbon ion therapy, renowned for exceptional care and service. Integrating ART-Plan with their cutting-edge methods could deliver the most precise, effective radiotherapy available, improving patient outcomes and further reducing side effects. 🔧 Leading the Way with AI: Art-Plan's AI-driven technology is designed to revolutionize precision oncology. Our solution enables hyper-personalized along with standardization, automation, increased throughput and the dissemination of best practices. 💡We are proud to work alongside MedAustron in our mission to shape the future of medicine. This partnership paves the way towards a world where AI and cutting-edge research bring new hope to cancer patients everywhere. Together with MedAustron, we are setting new standards in cancer care.

✨Hallo Nederland 🇳🇱 ! ART-Plan Precision Radiotherapy is now integrated into the world-class, renowned Amsterdam UMC's networks of hospitals clinical workflow! 📈At TheraPanacea, we're ecstatic to announce the adoption from Amsterdam UMC of our AI-powered ART-Plan Precision Radiotherapy Solution to the forefront of cancer treatment. This is a testament to our shared vision of harnessing the power of artificial intelligence to transform patient care. 🏥Amsterdam UMC is a premium cancer center in Netherlands exceling in cancer treatment using the most advanced techniques renowned for exceptional care, service and research initiatives. Integrating ART-Plan with their cutting-edge methods could deliver the most precise, effective radiotherapy available, improving patient outcomes and further reducing side effects. 🔧 Leading the Way with AI: Art-Plan's AI-driven technology is designed to revolutionize precision oncology. Our solution enables hyper-personalized along with standardization, automation, increased throughput and the dissemination of best practices. 💡We are proud to work alongside Amsterdam UMC in our mission to shape the future of medicine. This partnership paves the way towards a world where AI and cutting-edge research bring new hope to cancer patients everywhere. Together with Amsterdam UMC, we are setting new standards in cancer care.

Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer A Secondary Analysis of a Randomized Clinical Trial https://lnkd.in/gDGQM7hs

Using novel machine learning tools developed by SCI member Everett Moding and team, the researchers have mapped three distinct cellular configurations corresponding to clinical outcomes for patients with a rare, difficult-to-treat cancer called soft tissue sarcoma. In particular, the technique identified a cellular neighborhood that correlated with a positive response to immunotherapy, which may help physicians make treatment decisions. #sarcoma #immunotherapy https://stan.md/4cD0F49

#SpeakingofScience: In a recent breakthrough, Stanford University School of Medicine unveiled #AI-powered tools that offer new hope for treating soft tissue #sarcomas, a rare and challenging #cancer. The study mapped out distinct cellular configurations within these tumors, revealing insights into patient outcomes and #cancertreatment responses. One key finding is the identification of a cellular neighborhood linked to a positive response to #immunotherapy, potentially revolutionizing treatment approaches. Despite the cancer's complexity, #machinelearning techniques helped unravel crucial insights into the tumor microenvironment. This study challenges previous assumptions by suggesting that tumors with an intermediate level of immune cell infiltration may respond best to immunotherapy. Dr. Moding's team aims to validate these findings further, with the support of collaborative efforts and funding agencies. 🔬🚀 #CancerResearch #AI #Immunotherapy #PrecisionMedicine #StanfordMedicine #ClinicalResearch #Biotech #AIinhealthcare #MedTech #HealthcareInnovation #CancerDiscovery

📢 Check out this enlightening Original Article on AI bias in lung cancer radiotherapy! 🔗 Read more: https://lnkd.in/gD7FpyFC 📖 #lungcancerresearch #AIbias #DigitalHealth 👀

📢 Come on! An insightful OA is online!   🗨️ Title: AI bias in lung cancer radiotherapy   ✒️ Authors: Kai Ding*, Shelby Forbes, Fangfang Ma, Ganxi Luo, Jiayou Zhou, Yian Qi   🧠 In #lung cancer research, #AI has been trained to read #chest radiographs, which has led to improved health outcomes. However, the use of AI in healthcare settings is not without its own set of drawbacks, with bias being primary among them. This study seeks to investigate AI #bias in diagnosing and treating lung cancer patients.   🔗 Article Details View: https://lnkd.in/gD7FpyFC (P.S. Download as PDF for better viewing 👀 )   #ExplorDHT #DigitalHealth #lungcancer

Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT https://lnkd.in/dPf7BuKB